On Thursday, October 31, the European Commission imposed a fine of 462.6 million euros on the Israeli pharmaceutical group Teva, accusing it of “abuse of dominant position” for its multiple sclerosis treatment drug, Copaxone.
In a press release, Brussels accused Teva in particular of “systematically disseminating misleading information about a competing product to hinder its entry into the market”.
The Commission also criticizes the company for having “artificially” expanded the Copaxone patent, to put a brake on the wheels of its rivals. Teva is primarily a large industrial group specializing in generic medicines, but it also markets its own treatments, such as Copaxone.
Fifteen days ago, the US Department of Justice announced that the laboratory would pay 450 million dollars to end a civil lawsuit in the United States, linked to the payment of bribes to increase sales of Copaxone and an agreement on the price of a drug for cholesterol, pravastatin.
The contributions area is reserved for subscribers.
Subscribe to access this discussion space and contribute to the discussion.
Contribute
Reuse this content
